OFI Invest Asset Management Has $1.38 Million Stock Holdings in Boston Scientific Corporation $BSX

Key Points

• OFI Invest Asset Management increased its stake in Boston Scientific Corporation by 34.9% during the second quarter, valuing its holdings at approximately $1.38 million.
• Boston Scientific reported strong quarterly earnings with an EPS of $0.75, surpassing analysts' expectations of $0.72, and achieved a revenue of $5.06 billion, up 22.8% year-over-year.
• Several analysts have recently reaffirmed a "buy" rating for Boston Scientific, with target prices ranging from $121.00 to $135.00, indicating strong investor confidence in the stock.

OFI Invest Asset Management boosted its holdings in Boston Scientific Corporation (NYSE:BSX - Free Report) by 34.9% during the 2nd quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 12,817 shares of the medical equipment provider's stock after acquiring an additional 3,317 shares during the quarter. OFI Invest Asset Management's holdings in Boston Scientific were worth $1,377,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in BSX. Brighton Jones LLC lifted its position in Boston Scientific by 0.8% in the 4th quarter. Brighton Jones LLC now owns 27,376 shares of the medical equipment provider's stock valued at $2,445,000 after acquiring an additional 226 shares in the last quarter. Wealthcare Advisory Partners LLC lifted its position in Boston Scientific by 25.8% in the 1st quarter. Wealthcare Advisory Partners LLC now owns 3,675 shares of the medical equipment provider's stock valued at $371,000 after acquiring an additional 754 shares in the last quarter. GAMMA Investing LLC lifted its position in Boston Scientific by 17.2% in the 1st quarter. GAMMA Investing LLC now owns 25,554 shares of the medical equipment provider's stock valued at $2,578,000 after acquiring an additional 3,745 shares in the last quarter. Integrated Advisors Network LLC lifted its position in Boston Scientific by 4.5% in the 1st quarter. Integrated Advisors Network LLC now owns 6,836 shares of the medical equipment provider's stock valued at $690,000 after acquiring an additional 296 shares in the last quarter. Finally, West Branch Capital LLC lifted its position in Boston Scientific by 12,583.3% in the 1st quarter. West Branch Capital LLC now owns 761 shares of the medical equipment provider's stock valued at $77,000 after acquiring an additional 755 shares in the last quarter. Institutional investors own 89.07% of the company's stock.

Analyst Ratings Changes

Several equities analysts recently weighed in on BSX shares. Needham & Company LLC reaffirmed a "buy" rating and issued a $121.00 price target on shares of Boston Scientific in a research report on Wednesday, October 1st. Leerink Partnrs raised shares of Boston Scientific to a "strong-buy" rating in a research report on Monday, June 16th. Weiss Ratings reissued a "buy (b-)" rating on shares of Boston Scientific in a research report on Wednesday. Oppenheimer raised shares of Boston Scientific from a "market perform" rating to an "outperform" rating and lifted their target price for the stock from $118.00 to $125.00 in a research report on Monday, September 8th. Finally, UBS Group lifted their target price on shares of Boston Scientific from $130.00 to $135.00 and gave the stock a "buy" rating in a research report on Thursday, July 24th. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have given a Buy rating and two have issued a Hold rating to the stock. According to data from MarketBeat, the stock presently has a consensus rating of "Buy" and an average target price of $120.71.

Boston Scientific Trading Down 1.9%

NYSE:BSX opened at $95.41 on Friday. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49. The stock has a market capitalization of $141.38 billion, a PE ratio of 56.79, a price-to-earnings-growth ratio of 2.30 and a beta of 0.61. The firm's 50 day moving average is $101.98 and its 200 day moving average is $101.86. Boston Scientific Corporation has a 12 month low of $80.64 and a 12 month high of $109.50.

Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 EPS for the quarter, topping analysts' consensus estimates of $0.72 by $0.03. The company had revenue of $5.06 billion for the quarter, compared to analysts' expectations of $4.89 billion. Boston Scientific had a net margin of 13.55% and a return on equity of 19.21%. Boston Scientific's revenue was up 22.8% on a year-over-year basis. During the same quarter in the previous year, the firm posted $0.62 EPS. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Sell-side analysts expect that Boston Scientific Corporation will post 2.85 earnings per share for the current year.

Insider Activity at Boston Scientific

In related news, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction that occurred on Friday, August 1st. The shares were sold at an average price of $104.63, for a total value of $1,811,459.19. Following the sale, the executive vice president owned 23,600 shares of the company's stock, valued at approximately $2,469,268. The trade was a 42.32% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of Boston Scientific stock in a transaction that occurred on Friday, July 25th. The shares were sold at an average price of $106.03, for a total transaction of $424,120.00. Following the completion of the transaction, the director owned 18,479 shares of the company's stock, valued at $1,959,328.37. This represents a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 174,214 shares of company stock worth $17,972,457. Company insiders own 0.50% of the company's stock.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.

Want to see what other hedge funds are holding BSX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.